+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
NGAL Antibody Market by Application (Enzyme Linked Immunosorbent Assay, Flow Cytometry, Immunofluorescence), End User (Academic Centers, Diagnostic Laboratories, Hospitals), Product Type, Label Type, Clinical Indication - Global Forecast 2025-2030- Product Image
NGAL Antibody Market by Application (Enzyme Linked Immunosorbent Assay, Flow Cytometry, Immunofluorescence), End User (Academic Centers, Diagnostic Laboratories, Hospitals), Product Type, Label Type, Clinical Indication - Global Forecast 2025-2030- Product Image
New

NGAL Antibody Market by Application (Enzyme Linked Immunosorbent Assay, Flow Cytometry, Immunofluorescence), End User (Academic Centers, Diagnostic Laboratories, Hospitals), Product Type, Label Type, Clinical Indication - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 183 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6136875
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
Neutrophil gelatinase-associated lipocalin (NGAL) has emerged as an indispensable biomarker and research reagent in life sciences, driving significant advancements in early disease detection and therapeutic monitoring. Historically recognized for its role in acute kidney injury, NGAL has transcended conventional applications to become a focal point for understanding underlying pathophysiology of diverse conditions ranging from chronic renal disease to oncology. The precision and specificity afforded by NGAL antibody tools have transformed diagnostic laboratories and research institutes, providing clarity in cellular assays and tissue analyses.

Through rigorous assay development and validation, these antibodies have enabled academic centers and pharmaceutical biotech companies to achieve robust data reproducibility, accelerating translational studies and clinical trial readiness. As healthcare systems increasingly pivot toward personalized medicine and biomarker-driven approaches, the demand for high-quality NGAL antibodies has intensified. This introduction frames the scope of the report, outlining how NGAL antibody solutions are redefining diagnostic workflows and research methodologies. It sets the stage for an in-depth exploration of market dynamics, technological innovations, and strategic imperatives that are shaping the future of this critical reagent segment.

Transformational Breakthroughs in NGAL Antibody Technology Are Redefining Disease Detection, Prognostic Precision, and Biomarker Research Methodologies

Recent breakthroughs in antibody engineering have catalyzed a transformative shift in the NGAL antibody landscape, driving enhanced sensitivity and specificity in detection platforms. Manufacturers have leveraged recombinant antibody technology to overcome the limitations of traditional polyclonal reagents, yielding homogenous biomolecules that ensure consistent performance across multiplex assays. Simultaneously, the integration of fluorescent labels and enzyme-conjugation techniques has facilitated real-time imaging and high-throughput screening, bridging the gap between qualitative observations and quantitative data.

Simultaneously, clinical laboratories have adopted automation for immunohistochemistry workflows, reducing turnaround times while maintaining staining fidelity. The convergence of these innovations with advanced flow cytometry and sandwich ELISA formats has propelled NGAL into new areas of research relevance, including sepsis diagnostics and biomarker discovery pipelines. These shifts underscore a move from single-use, manual assays toward integrated, automated platforms that support scalable operations and cross-disciplinary investigations. As these technological trends continue to mature, the NGAL antibody domain stands at the nexus of precision diagnostics and next-generation therapeutic research, promising to redefine standard-of-care protocols.

Assessing the Broad Repercussions of Newly Enacted United States Tariffs in 2025 on the Supply Chain Dynamics and Affordability of NGAL Antibodies

The imposition of new United States tariffs in 2025 has introduced a paradigm shift in global supply chains for NGAL antibodies, compelling manufacturers and end users to reassess sourcing strategies and cost structures. Raw materials and specialized reagents imported into North America now bear additional duties, prompting some companies to explore alternative suppliers in regions with more favorable trade agreements. This recalibration has led to extended lead times for critical antibodies, necessitating proactive inventory management in diagnostic laboratories and research facilities.

These trade policy adjustments have also driven collaborations between domestic producers and international partners, aiming to localize portions of the manufacturing process. While this strategy mitigates exposure to tariff-related cost increases, it requires substantial investments in technology transfer and quality assurance. Financial pressures arising from duty escalations have in some cases been passed onto end users, influencing budgeting cycles within hospitals and pharmaceutical companies. Nevertheless, stakeholders are leveraging this challenge as an opportunity to strengthen regional production capacities and to negotiate long-term contracts that stabilize supply and pricing amid an evolving regulatory environment.

Unraveling Key Market Segments by Application, End User, Product Type, Label Type, and Clinical Indication to Guide Strategic Positioning of NGAL Antibodies

A granular understanding of market segmentation is critical for stakeholders to tailor development and commercialization strategies for NGAL antibodies. Application diversity spans quantitative immunoassays, advanced flow cytometry platforms, and both manual and automated immunohistochemistry protocols, with further distinctions among competitive, indirect, and sandwich ELISA formats that cater to varied sensitivity and throughput requirements. Each assay type demands optimized antibody characteristics, from epitope specificity to label compatibility.

End users encompass academic research centers driving exploratory science, high-throughput diagnostic laboratories requiring scalable solutions, hospital pathology units prioritizing clinical turnaround, and pharmaceutical biotech organizations seeking biomarker validation for drug development programs. Research institutes focused on translational applications also rely heavily on bespoke antibody reagents. Product offerings range from monoclonal antibodies delivering batch-to-batch consistency to polyclonal reagents that offer broader epitope recognition, alongside emerging recombinant formats engineered for superior affinity.

Label technologies are equally varied, spanning biotin and enzyme conjugates for colorimetric assays, fluorescent tags for multiplex imaging, and radioisotope labels for specialized detection methods. Clinical indications undergoing intensive investigation include acute kidney injury diagnostics, chronic kidney disease monitoring, sepsis biomarker profiling, and basic biomarker research efforts that promise to uncover new therapeutic targets. These dimensions collectively inform strategic decisions around pipeline prioritization and resource allocation.

Delineating Regional Dynamics across Americas, Europe Middle East and Africa, and Asia Pacific to Illuminate Growth Drivers for NGAL Antibody Adoption

Regional dynamics are shaping the trajectory of the NGAL antibody market, with the Americas leading through robust investment in clinical research infrastructure and a high adoption rate of automated diagnostic platforms. North American stakeholders benefit from well-established distribution networks and supportive regulatory frameworks that expedite antibody validation for clinical use. Latin American markets, while emerging, demonstrate increasing interest in biomarker-driven diagnostics, spurring partnerships to broaden reagent accessibility and training initiatives.

The Europe, Middle East, and Africa region offers a diverse landscape where Western European countries drive innovation with strong public-private collaborations, while emerging markets in Eastern Europe and the Middle East focus on expanding laboratory capacities. Regulatory harmonization efforts are facilitating cross-border reagent standardization, creating new opportunities for antibody providers. In the Asia-Pacific region, rapid expansion in research funding, government-led precision medicine programs, and burgeoning biotech hubs are accelerating demand. Countries such as China, Japan, and South Korea are not only significant consumers of NGAL antibodies but also contributors to assay development, positioning the region as both a market and a source of innovation.

Profiling Leading Innovators and Strategic Collaborations That Are Shaping the Competitive Landscape of the NGAL Antibody Market

Industry leaders in the NGAL antibody space are forging strategic collaborations and investing in novel engineering platforms to maintain competitive advantage. Established life science suppliers are expanding their monoclonal antibody portfolios while integrating recombinant techniques to deliver higher affinity reagents. At the same time, agile biotech firms are focusing on niche applications, such as fluorescence-based imaging probes and radioisotope-conjugated antibodies, to address specialized research needs.

Collaborative initiatives between antibody manufacturers and diagnostic instrumentation companies are yielding end-to-end solutions that streamline assay workflows and enhance data reproducibility. Partnerships with academic institutions are accelerating the translation of NGAL biomarker research into clinical assays, fostering a continuous feedback loop between discovery science and product development. Additionally, strategic licensing deals and joint ventures are facilitating access to proprietary epitope libraries, empowering companies to diversify product offerings without duplicating internal R&D expenditure. These competitive maneuvers underscore a market characterized by both consolidation among large providers and targeted innovation by emerging players.

Strategic Imperatives and Actionable Recommendations for Industry Leaders to Capitalize on Emerging Opportunities and Mitigate Risks in the NGAL Antibody Sector

To capitalize on the unfolding opportunities in the NGAL antibody sector, industry leaders should prioritize agile supply chain structures that accommodate tariff fluctuations and regulatory shifts. Investing in dual sourcing strategies and regional manufacturing alliances will build resilience and ensure uninterrupted reagent availability. Concurrently, organizations should deepen partnerships with clinical laboratories and research institutes to co-develop assays that meet evolving throughput and sensitivity requirements, thereby solidifying customer loyalty and driving co-marketing opportunities.

Innovative product differentiation-through advanced labeling chemistries, next-generation recombinant formats, and assay automation compatibility-will distinguish market leaders from competitors. Allocating resources to real-world evidence generation and peer-reviewed publications will enhance credibility and support premium pricing models. Furthermore, companies should engage regulatory bodies early to streamline validation pathways for novel antibody formats, reducing time-to-market. Finally, leveraging digital platforms for customer engagement, training, and technical support will foster stronger relationships and accelerate adoption of new NGAL antibody solutions.

Transparent Overview of Research Methodology Emphasizing Data Sources, Analytical Frameworks, and Validation Processes Underpinning the NGAL Antibody Market Analysis

This analysis combines primary and secondary research methodologies to deliver a comprehensive view of the NGAL antibody market. Primary research involved in-depth interviews with key opinion leaders, assay development specialists, and procurement managers across diagnostic laboratories, academic centers, and pharmaceutical companies. These qualitative insights were supplemented with data collected from publicly available regulatory filings, peer-reviewed literature, and patent databases to validate technology trends.

Secondary sources included industry publications, conference proceedings, and established scientific databases focused on antibody engineering and biomarker discovery. An iterative triangulation process was applied to reconcile divergent viewpoints and ensure data integrity. A combination of SWOT analysis, competitive benchmarking, and trend impact assessment provided the analytical foundation to interpret market dynamics. Regional analyses incorporated trade data and regulatory developments to reflect localized nuances. All findings were peer reviewed by domain experts to maintain methodological rigor and objectivity throughout the study.

Synthesis of Insights and Forward-Looking Perspectives Highlighting the Critical Role of NGAL Antibodies in Future Diagnostics and Therapeutic Research

The insights presented underscore the mounting importance of NGAL antibodies as pivotal tools in both diagnostic and research domains, driven by advances in assay design, labeling technologies, and recombinant engineering. Supply chain complexities introduced by recent tariff policies are encouraging stakeholders to reassess sourcing strategies and fortify regional capabilities, while segmentation nuances inform targeted go-to-market approaches across applications, end users, and clinical indications. Competitive dynamics remain vibrant, characterized by alliances that bridge discovery science with commercial product offerings.

Forward-looking strategies will hinge on product differentiation, strategic collaborations, and evidence-based validation to meet evolving demands for sensitivity, specificity, and operational efficiency. As regional markets mature and novel clinical applications emerge, organizations that adapt swiftly and invest in scalable, high-performance antibody solutions will capture the greatest value. The confluence of innovation, regulation, and market diversification signals a robust future for NGAL antibody technologies.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Application
    • Enzyme Linked Immunosorbent Assay
      • Competitive Enzyme Linked Immunosorbent Assay
      • Indirect Enzyme Linked Immunosorbent Assay
      • Sandwich Enzyme Linked Immunosorbent Assay
    • Flow Cytometry
    • Immunofluorescence
    • Immunohistochemistry
      • Automated Immunohistochemistry
      • Manual Immunohistochemistry
    • Western Blotting
  • End User
    • Academic Centers
    • Diagnostic Laboratories
    • Hospitals
    • Pharmaceutical Biotech Companies
    • Research Institutes
  • Product Type
    • Monoclonal Antibody
    • Polyclonal Antibody
    • Recombinant Antibody
  • Label Type
    • Biotin Labeled
    • Enzyme Labeled
    • Fluorescent Labeled
    • Radioisotope Labeled
  • Clinical Indication
    • Acute Kidney Injury
    • Biomarker Research
    • Chronic Kidney Disease
    • Sepsis Diagnosis
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Bio-Techne Corporation
  • Abcam plc
  • BioVendor-Laboratorní medicína a.s.
  • RayBiotech, Inc.
  • Sino Biological Inc.
  • MyBioSource, Inc.
  • Proteintech Group, Inc.
  • Santa Cruz Biotechnology, Inc.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Rising adoption of NGAL antibody assays in early acute kidney injury diagnosis across hospitals
5.2. Increasing integration of NGAL antibody-based point-of-care tests in outpatient nephrology clinics
5.3. Advancements in monoclonal NGAL antibody engineering for enhanced assay sensitivity and specificity
5.4. Strategic partnerships between diagnostic companies and biotech firms to expand NGAL antibody applications
5.5. Growing investment in multiplex biomarker panels including NGAL antibody for comprehensive renal disease screening
5.6. Regulatory approval trends and reimbursement landscape shaping NGAL antibody diagnostic market access
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. NGAL Antibody Market, by Application
8.1. Introduction
8.2. Enzyme Linked Immunosorbent Assay
8.2.1. Competitive Enzyme Linked Immunosorbent Assay
8.2.2. Indirect Enzyme Linked Immunosorbent Assay
8.2.3. Sandwich Enzyme Linked Immunosorbent Assay
8.3. Flow Cytometry
8.4. Immunofluorescence
8.5. Immunohistochemistry
8.5.1. Automated Immunohistochemistry
8.5.2. Manual Immunohistochemistry
8.6. Western Blotting
9. NGAL Antibody Market, by End User
9.1. Introduction
9.2. Academic Centers
9.3. Diagnostic Laboratories
9.4. Hospitals
9.5. Pharmaceutical Biotech Companies
9.6. Research Institutes
10. NGAL Antibody Market, by Product Type
10.1. Introduction
10.2. Monoclonal Antibody
10.3. Polyclonal Antibody
10.4. Recombinant Antibody
11. NGAL Antibody Market, by Label Type
11.1. Introduction
11.2. Biotin Labeled
11.3. Enzyme Labeled
11.4. Fluorescent Labeled
11.5. Radioisotope Labeled
12. NGAL Antibody Market, by Clinical Indication
12.1. Introduction
12.2. Acute Kidney Injury
12.3. Biomarker Research
12.4. Chronic Kidney Disease
12.5. Sepsis Diagnosis
13. Americas NGAL Antibody Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa NGAL Antibody Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific NGAL Antibody Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Thermo Fisher Scientific Inc.
16.3.2. Merck KGaA
16.3.3. Bio-Techne Corporation
16.3.4. Abcam plc
16.3.5. BioVendor-Laboratorní medicína a.s.
16.3.6. RayBiotech, Inc.
16.3.7. Sino Biological Inc.
16.3.8. MyBioSource, Inc.
16.3.9. Proteintech Group, Inc.
16.3.10. Santa Cruz Biotechnology, Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. NGAL ANTIBODY MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL NGAL ANTIBODY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL NGAL ANTIBODY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL NGAL ANTIBODY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL NGAL ANTIBODY MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL NGAL ANTIBODY MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL NGAL ANTIBODY MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 8. GLOBAL NGAL ANTIBODY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL NGAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL NGAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL NGAL ANTIBODY MARKET SIZE, BY LABEL TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL NGAL ANTIBODY MARKET SIZE, BY LABEL TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL NGAL ANTIBODY MARKET SIZE, BY CLINICAL INDICATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL NGAL ANTIBODY MARKET SIZE, BY CLINICAL INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS NGAL ANTIBODY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS NGAL ANTIBODY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES NGAL ANTIBODY MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES NGAL ANTIBODY MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA NGAL ANTIBODY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA NGAL ANTIBODY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC NGAL ANTIBODY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC NGAL ANTIBODY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. NGAL ANTIBODY MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. NGAL ANTIBODY MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. NGAL ANTIBODY MARKET: RESEARCHAI
FIGURE 26. NGAL ANTIBODY MARKET: RESEARCHSTATISTICS
FIGURE 27. NGAL ANTIBODY MARKET: RESEARCHCONTACTS
FIGURE 28. NGAL ANTIBODY MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. NGAL ANTIBODY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL NGAL ANTIBODY MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL NGAL ANTIBODY MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL NGAL ANTIBODY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL NGAL ANTIBODY MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL NGAL ANTIBODY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL NGAL ANTIBODY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL NGAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL NGAL ANTIBODY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL NGAL ANTIBODY MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL NGAL ANTIBODY MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL NGAL ANTIBODY MARKET SIZE, BY COMPETITIVE ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL NGAL ANTIBODY MARKET SIZE, BY COMPETITIVE ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL NGAL ANTIBODY MARKET SIZE, BY INDIRECT ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL NGAL ANTIBODY MARKET SIZE, BY INDIRECT ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL NGAL ANTIBODY MARKET SIZE, BY SANDWICH ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL NGAL ANTIBODY MARKET SIZE, BY SANDWICH ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL NGAL ANTIBODY MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL NGAL ANTIBODY MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL NGAL ANTIBODY MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL NGAL ANTIBODY MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL NGAL ANTIBODY MARKET SIZE, BY IMMUNOFLUORESCENCE, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL NGAL ANTIBODY MARKET SIZE, BY IMMUNOFLUORESCENCE, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL NGAL ANTIBODY MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL NGAL ANTIBODY MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL NGAL ANTIBODY MARKET SIZE, BY AUTOMATED IMMUNOHISTOCHEMISTRY, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL NGAL ANTIBODY MARKET SIZE, BY AUTOMATED IMMUNOHISTOCHEMISTRY, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL NGAL ANTIBODY MARKET SIZE, BY MANUAL IMMUNOHISTOCHEMISTRY, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL NGAL ANTIBODY MARKET SIZE, BY MANUAL IMMUNOHISTOCHEMISTRY, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL NGAL ANTIBODY MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL NGAL ANTIBODY MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL NGAL ANTIBODY MARKET SIZE, BY WESTERN BLOTTING, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL NGAL ANTIBODY MARKET SIZE, BY WESTERN BLOTTING, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL NGAL ANTIBODY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL NGAL ANTIBODY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL NGAL ANTIBODY MARKET SIZE, BY ACADEMIC CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL NGAL ANTIBODY MARKET SIZE, BY ACADEMIC CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL NGAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL NGAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL NGAL ANTIBODY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL NGAL ANTIBODY MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL NGAL ANTIBODY MARKET SIZE, BY PHARMACEUTICAL BIOTECH COMPANIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL NGAL ANTIBODY MARKET SIZE, BY PHARMACEUTICAL BIOTECH COMPANIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL NGAL ANTIBODY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL NGAL ANTIBODY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL NGAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL NGAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL NGAL ANTIBODY MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL NGAL ANTIBODY MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL NGAL ANTIBODY MARKET SIZE, BY POLYCLONAL ANTIBODY, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL NGAL ANTIBODY MARKET SIZE, BY POLYCLONAL ANTIBODY, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL NGAL ANTIBODY MARKET SIZE, BY RECOMBINANT ANTIBODY, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL NGAL ANTIBODY MARKET SIZE, BY RECOMBINANT ANTIBODY, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL NGAL ANTIBODY MARKET SIZE, BY LABEL TYPE, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL NGAL ANTIBODY MARKET SIZE, BY LABEL TYPE, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL NGAL ANTIBODY MARKET SIZE, BY BIOTIN LABELED, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL NGAL ANTIBODY MARKET SIZE, BY BIOTIN LABELED, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL NGAL ANTIBODY MARKET SIZE, BY ENZYME LABELED, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL NGAL ANTIBODY MARKET SIZE, BY ENZYME LABELED, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL NGAL ANTIBODY MARKET SIZE, BY FLUORESCENT LABELED, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL NGAL ANTIBODY MARKET SIZE, BY FLUORESCENT LABELED, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL NGAL ANTIBODY MARKET SIZE, BY RADIOISOTOPE LABELED, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL NGAL ANTIBODY MARKET SIZE, BY RADIOISOTOPE LABELED, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL NGAL ANTIBODY MARKET SIZE, BY CLINICAL INDICATION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL NGAL ANTIBODY MARKET SIZE, BY CLINICAL INDICATION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL NGAL ANTIBODY MARKET SIZE, BY ACUTE KIDNEY INJURY, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL NGAL ANTIBODY MARKET SIZE, BY ACUTE KIDNEY INJURY, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL NGAL ANTIBODY MARKET SIZE, BY BIOMARKER RESEARCH, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL NGAL ANTIBODY MARKET SIZE, BY BIOMARKER RESEARCH, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL NGAL ANTIBODY MARKET SIZE, BY CHRONIC KIDNEY DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL NGAL ANTIBODY MARKET SIZE, BY CHRONIC KIDNEY DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL NGAL ANTIBODY MARKET SIZE, BY SEPSIS DIAGNOSIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL NGAL ANTIBODY MARKET SIZE, BY SEPSIS DIAGNOSIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS NGAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS NGAL ANTIBODY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS NGAL ANTIBODY MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS NGAL ANTIBODY MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS NGAL ANTIBODY MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS NGAL ANTIBODY MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS NGAL ANTIBODY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS NGAL ANTIBODY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS NGAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS NGAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS NGAL ANTIBODY MARKET SIZE, BY LABEL TYPE, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS NGAL ANTIBODY MARKET SIZE, BY LABEL TYPE, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS NGAL ANTIBODY MARKET SIZE, BY CLINICAL INDICATION, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS NGAL ANTIBODY MARKET SIZE, BY CLINICAL INDICATION, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS NGAL ANTIBODY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS NGAL ANTIBODY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES NGAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES NGAL ANTIBODY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES NGAL ANTIBODY MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES NGAL ANTIBODY MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES NGAL ANTIBODY MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES NGAL ANTIBODY MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES NGAL ANTIBODY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES NGAL ANTIBODY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 99. UNITED STATES NGAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 100. UNITED STATES NGAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 101. UNITED STATES NGAL ANTIBODY MARKET SIZE, BY LABEL TYPE, 2018-2024 (USD MILLION)
TABLE 102. UNITED STATES NGAL ANTIBODY MARKET SIZE, BY LABEL TYPE, 2025-2030 (USD MILLION)
TABLE 103. UNITED STATES NGAL ANTIBODY MARKET SIZE, BY CLINICAL INDICATION, 2018-2024 (USD MILLION)
TABLE 104. UNITED STATES NGAL ANTIBODY MARKET SIZE, BY CLINICAL INDICATION, 2025-2030 (USD MILLION)
TABLE 105. UNITED STATES NGAL ANTIBODY MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 106. UNITED STATES NGAL ANTIBODY MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 107. CANADA NGAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 108. CANADA NGAL ANTIBODY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 109. CANADA NGAL ANTIBODY MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2018-2024 (USD MILLION)
TABLE 110. CANADA NGAL ANTIBODY MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2025-2030 (USD MILLION)
TABLE 111. CANADA NGAL ANTIBODY MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2024 (USD MILLION)
TABLE 112. CANADA NGAL ANTIBODY MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2025-2030 (USD MILLION)
TABLE 113. CANADA NGAL ANTIBODY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 114. CANADA NGAL ANTIBODY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 115. CANADA NGAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 116. CANADA NGAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 117. CANADA NGAL ANTIBODY MARKET SIZE, BY LABEL TYPE, 2018-2024 (USD MILLION)
TABLE 118. CANADA NGAL ANTIBODY MARKET SIZE, BY LABEL TYPE, 2025-2030 (USD MILLION)
TABLE 119. CANADA NGAL ANTIBODY MARKET SIZE, BY CLINICAL INDICATION, 2018-2024 (USD MILLION)
TABLE 120. CANADA NGAL ANTIBODY MARKET SIZE, BY CLINICAL INDICATION, 2025-2030 (USD MILLION)
TABLE 121. MEXICO NGAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 122. MEXICO NGAL ANTIBODY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 123. MEXICO NGAL ANTIBODY MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2018-2024 (USD MILLION)
TABLE 124. MEXICO NGAL ANTIBODY MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2025-2030 (USD MILLION)
TABLE 125. MEXICO NGAL ANTIBODY MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2024 (USD MILLION)
TABLE 126. MEXICO NGAL ANTIBODY MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2025-2030 (USD MILLION)
TABLE 127. MEXICO NGAL ANTIBODY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 128. MEXICO NGAL ANTIBODY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 129. MEXICO NGAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 130. MEXICO NGAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 131. MEXICO NGAL ANTIBODY MARKET SIZE, BY LABEL TYPE, 2018-2024 (USD MILLION)
TABLE 132. MEXICO NGAL ANTIBODY MARKET SIZE, BY LABEL TYPE, 2025-2030 (USD MILLION)
TABLE 133. MEXICO NGAL ANTIBODY MARKET SIZE, BY CLINICAL INDICATION, 2018-2024 (USD MILLION)
TABLE 134. MEXICO NGAL ANTIBODY MARKET SIZE, BY CLINICAL INDICATION, 2025-2030 (USD MILLION)
TABLE 135. BRAZIL NGAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 136. BRAZIL NGAL ANTIBODY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 137. BRAZIL NGAL ANTIBODY MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2018-2024 (USD MILLION)
TABLE 138. BRAZIL NGAL ANTIBODY MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2025-2030 (USD MILLION)
TABLE 139. BRAZIL NGAL ANTIBODY MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2024 (USD MILLION)
TABLE 140. BRAZIL NGAL ANTIBODY MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2025-2030 (USD MILLION)
TABLE 141. BRAZIL NGAL ANTIBODY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 142. BRAZIL NGAL ANTIBODY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 143. BRAZIL NGAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 144. BRAZIL NGAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 145. BRAZIL NGAL ANTIBODY MARKET SIZE, BY LABEL TYPE, 2018-2024 (USD MILLION)
TABLE 146. BRAZIL NGAL ANTIBODY MARKET SIZE, BY LABEL TYPE, 2025-2030 (USD MILLION)
TABLE 147. BRAZIL NGAL ANTIBODY MARKET SIZE, BY CLINICAL INDICATION, 2018-2024 (USD MILLION)
TABLE 148. BRAZIL NGAL ANTIBODY MARKET SIZE, BY CLINICAL INDICATION, 2025-2030 (USD MILLION)
TABLE 149. ARGENTINA NGAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 150. ARGENTINA NGAL ANTIBODY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 151. ARGENTINA NGAL ANTIBODY MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2018-2024 (USD MILLION)
TABLE 152. ARGENTINA NGAL ANTIBODY MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2025-2030 (USD MILLION)
TABLE 153. ARGENTINA NGAL ANTIBODY MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2024 (USD MILLION)
TABLE 154. ARGENTINA NGAL ANTIBODY MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2025-2030 (USD MILLION)
TABLE 155. ARGENTINA NGAL ANTIBODY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 156. ARGENTINA NGAL ANTIBODY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 157. ARGENTINA NGAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 158. ARGENTINA NGAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 159. ARGENTINA NGAL ANTIBODY MARKET SIZE, BY LABEL TYPE, 2018-2024 (USD MILLION)
TABLE 160. ARGENTINA NGAL ANTIBODY MARKET SIZE, BY LABEL TYPE, 2025-2030 (USD MILLION)
TABLE 161. ARGENTINA NGAL ANTIBODY MARKET SIZE, BY CLINICAL INDICATION, 2018-2024 (USD MILLION)
TABLE 162. ARGENTINA NGAL ANTIBODY MARKET SIZE, BY CLINICAL INDICATION, 2025-2030 (USD MILLION)
TABLE 163. EUROPE, MIDDLE EAST & AFRICA NGAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 164. EUROPE, MIDDLE EAST & AFRICA NGAL ANTIBODY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 165. EUROPE, MIDDLE EAST & AFRICA NGAL ANTIBODY MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2018-2024 (USD MILLION)
TABLE 166. EUROPE, MIDDLE EAST & AFRICA NGAL ANTIBODY MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2025-2030 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA NGAL ANTIBODY MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2024 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA NGAL ANTIBODY MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2025-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA NGAL ANTIBODY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA NGAL ANTIBODY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA NGAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA NGAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA NGAL ANTIBODY MARKET SIZE, BY LABEL TYPE, 2018-2024 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA NGAL ANTIBODY MARKET SIZE, BY LABEL TYPE, 2025-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA NGAL ANTIBODY MARKET SIZE, BY CLINICAL INDICATION, 2018-2024 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA NGAL ANTIBODY MARKET SIZE, BY CLINICAL INDICATION, 2025-2030 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA NGAL ANTIBODY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA NGAL ANTIBODY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 179. UNITED KINGDOM NGAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 180. UNITED KINGDOM NGAL ANTIBODY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 181. UNITED KINGDOM NGAL ANTIBODY MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2018-2024 (USD MILLION)
TABLE 182. UNITED KINGDOM NGAL ANTIBODY MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2025-2030 (USD MILLION)
TABLE 183. UNITED KINGDOM NGAL ANTIBODY MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2024 (USD MILLION)
TABLE 184. UNITED KINGDOM NGAL ANTIBODY MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2025-2030 (USD MILLION)
TABLE 185. UNITED KINGDOM NGAL ANTIBODY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 186. UNITED KINGDOM NGAL ANTIBODY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM NGAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 188. UNITED KINGDOM NGAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM NGAL ANTIBODY MARKET SIZE, BY LABEL TYPE, 2018-2024 (USD MILLION)
TABLE 190. UNITED KINGDOM NGAL ANTIBODY MARKET SIZE, BY LABEL TYPE, 2025-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM NGAL ANTIBODY MARKET SIZE, BY CLINICAL INDICATION, 2018-2024 (USD MILLION)
TABLE 192. UNITED KINGDOM NGAL ANTIBODY MARKET SIZE, BY CLINICAL INDICATION, 2025-2030 (USD MILLION)
TABLE 193. GERMANY NGAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 194. GERMANY NGAL ANTIBODY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 195. GERMANY NGAL ANTIBODY MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2018-2024 (USD MILLION)
TABLE 196. GERMANY NGAL ANTIBODY MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2025-2030 (USD MILLION)
TABLE 197. GERMANY NGAL ANTIBODY MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2024 (USD MILLION)
TABLE 198. GERMANY NGAL ANTIBODY MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2025-2030 (USD MILLION)
TABLE 199. GERMANY NGAL ANTIBODY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 200. GERMANY NGAL ANTIBODY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 201. GERMANY NGAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 202. GERMANY NGAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 203. GERMANY NGAL ANTIBODY MARKET SIZE, BY LABEL TYPE, 2018-2024 (USD MILLION)
TABLE 204. GERMANY NGAL ANTIBODY MARKET SIZE, BY LABEL TYPE, 2025-2030 (USD MILLION)
TABLE 205. GERMANY NGAL ANTIBODY MARKET SIZE, BY CLINICAL INDICATION, 2018-2024 (USD MILLION)
TABLE 206. GERMANY NGAL ANTIBODY MARKET SIZE, BY CLINICAL INDICATION, 2025-2030 (USD MILLION)
TABLE 207. FRANCE NGAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 208. FRANCE NGAL ANTIBODY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 209. FRANCE NGAL ANTIBODY MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2018-2024 (USD MILLION)
TABLE 210. FRANCE NGAL ANTIBODY MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2025-2030 (USD MILLION)
TABLE 211. FRANCE NGAL ANTIBODY MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2024 (USD MILLION)
TABLE 212. FRANCE NGAL ANTIBODY MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2025-2030 (USD MILLION)
TABLE 213. FRANCE NGAL ANTIBODY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 214. FRANCE NGAL ANTIBODY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 215. FRANCE NGAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 216. FRANCE NGAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 217. FRANCE NGAL ANTIBODY MARKET SIZE, BY LABEL TYPE, 2018-2024 (USD MILLION)
TABLE 218. FRANCE NGAL ANTIBODY MARKET SIZE, BY LABEL TYPE, 2025-2030 (USD MILLION)
TABLE 219. FRANCE NGAL ANTIBODY MARKET SIZE, BY CLINICAL INDICATION, 2018-2024 (USD MILLION)
TABLE 220. FRANCE NGAL ANTIBODY MARKET SIZE, BY CLINICAL INDICATION, 2025-2030 (USD MILLION)
TABLE 221. RUSSIA NGAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 222. RUSSIA NGAL ANTIBODY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 223. RUSSIA NGAL ANTIBODY MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2018-2024 (USD MILLION)
TABLE 224. RUSSIA NGAL ANTIBODY MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2025-2030 (USD MILLION)
TABLE 225. RUSSIA NGAL ANTIBODY MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2024 (USD MILLION)
TABLE 226. RUSSIA NGAL ANTIBODY MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2025-2030 (USD MILLION)
TABLE 227. RUSSIA NGAL ANTIBODY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 228. RUSSIA NGAL ANTIBODY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 229. RUSSIA NGAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 230. RUSSIA NGAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 231. RUSSIA NGAL ANTIBODY MARKET SIZE, BY LABEL TYPE, 2018-2024 (USD MILLION)
TABLE 232. RUSSIA NGAL ANTIBODY MARKET SIZE, BY LABEL TYPE, 2025-2030 (USD MILLION)
TABLE 233. RUSSIA NGAL ANTIBODY MARKET SIZE, BY CLINICAL INDICATION, 2018-2024 (USD MILLION)
TABLE 234. RUSSIA NGAL ANTIBODY MARKET SIZE, BY CLINICAL INDICATION, 2025-2030 (USD MILLION)
TABLE 235. ITALY NGAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 236. ITALY NGAL ANTIBODY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 237. ITALY NGAL ANTIBODY MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2018-2024 (USD MILLION)
TABLE 238. ITALY NGAL ANTIBODY MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2025-2030 (USD MILLION)
TABLE 239. ITALY NGAL ANTIBODY MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2024 (USD MILLION)
TABLE 240. ITALY NGAL ANTIBODY MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2025-2030 (USD MILLION)
TABLE 241. ITALY NGAL ANTIBODY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 242. ITALY NGAL ANTIBODY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 243. ITALY NGAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 244. ITALY NGAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 245. ITALY NGAL ANTIBODY MARKET SIZE, BY LABEL TYPE, 2018-2024 (USD MILLION)
TABLE 246. ITALY NGAL ANTIBODY MARKET SIZE, BY LABEL TYPE, 2025-2030 (USD MILLION)
TABLE 247. ITALY NGAL ANTIBODY MARKET SIZE, BY CLINICAL INDICATION, 2018-2024 (USD MILLION)
TABLE 248. ITALY NGAL ANTIBODY MARKET SIZE, BY CLINICAL INDICATION, 2025-2030 (USD MILLION)
TABLE 249. SPAIN NGAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 250. SPAIN NGAL ANTIBODY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 251. SPAIN NGAL ANTIBODY MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2018-2024 (USD MILLION)
TABLE 252. SPAIN NGAL ANTIBODY MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2025-2030 (USD MILLION)
TABLE 253. SPAIN NGAL ANTIBODY MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2024 (USD MILLION)
TABLE 254. SPAIN NGAL ANTIBODY MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2025-2030 (USD MILLION)
TABLE 255. SPAIN NGAL ANTIBODY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 256. SPAIN NGAL ANTIBODY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 257. SPAIN NGAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 258. SPAIN NGAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 259. SPAIN NGAL ANTIBODY MARKET SIZE, BY LABEL TYPE, 2018-2024 (USD MILLION)
TABLE 260. SPAIN NGAL ANTIBODY MARKET SIZE, BY LABEL TYPE, 2025-2030 (USD MILLION)
TABLE 261. SPAIN NGAL ANTIBODY MARKET SIZE, BY CLINICAL INDICATION, 2018-2024 (USD MILLION)
TABLE 262. SPAIN NGAL ANTIBODY MARKET SIZE, BY CLINICAL INDICATION, 2025-2030 (USD MILLION)
TABLE 263. UNITED ARAB EMIRATES NGAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 264. UNITED ARAB EMIRATES NGAL ANTIBODY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 265. UNITED ARAB EMIRATES NGAL ANTIBODY MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2018-2024 (USD MILLION)
TABLE 266. UNITED ARAB EMIRATES NGAL ANTIBODY MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2025-2030 (USD MILLION)
TABLE 267. UNITED ARAB EMIRATES NGAL ANTIBODY MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2024 (USD MILLION)
TABLE 268. UNITED ARAB EMIRATES NGAL ANTIBODY MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2025-2030 (USD MILLION)
TABLE 269. UNITED ARAB EMIRATES NGAL ANTIBODY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 270. UNITED ARAB EMIRATES NGAL ANTIBODY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 271. UNITED ARAB EMIRATES NGAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 272. UNITED ARAB EMIRATES NGAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 273. UNITED ARAB EMIRATES NGAL ANTIBODY MARKET SIZE, BY LABEL TYPE, 2018-2024 (USD MILLION)
TABLE 274. UNITED ARAB EMIRATES NGAL ANTIBODY MARKET SIZE, BY LABEL TYPE, 2025-2030 (USD MILLION)
TABLE 275. UNITED ARAB EMIRATES NGAL ANTIBODY MARKET SIZE, BY CLINICAL INDICATION, 2018-2024 (USD MILLION)
TABLE 276. UNITED ARAB EMIRATES NGAL ANTIBODY MARKET SIZE, BY CLINICAL INDICATION, 2025-2030 (USD MILLION)
TABLE 277. SAUDI ARABIA NGAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 278. SAUDI ARABIA NGAL ANTIBODY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 279. SAUDI ARABIA NGAL ANTIBODY MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2018-2024 (USD MILLION)
TABLE 280. SAUDI ARABIA NGAL ANTIBODY MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2025-2030 (USD MILLION)
TABLE 281. SAUDI ARABIA NGAL ANTIBODY MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2024 (USD MILLION)
TABLE 282. SAUDI ARABIA NGAL ANTIBODY MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2025-2030 (USD MILLION)
TABLE 283. SAUDI ARABIA NGAL ANTIBODY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 284. SAUDI ARABIA NGAL ANTIBODY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 285. SAUDI ARABIA NGAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 286. SAUDI ARABIA NGAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 287. SAUDI ARABIA NGAL ANTIBODY MARKET SIZE, BY LABEL TYPE, 2018-2024 (USD MILLION)
TABLE 288. SAUDI ARABIA NGAL ANTIBODY MARKET SIZE, BY LABEL TYPE, 2025-2030 (USD MILLION)
TABLE 289. SAUDI ARABIA NGAL ANTIBODY MARKET SIZE, BY CLINICAL INDICATION, 2018-2024 (USD MILLION)
TABLE 290. SAUDI ARABIA NGAL ANTIBODY MARKET SIZE, BY CLINICAL INDICATION, 2025-2030 (USD MILLION)
TABLE 291. SOUTH AFRICA NGAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 292. SOUTH AFRICA NGAL ANTIBODY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 293. SOUTH AFRICA NGAL ANTIBODY MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2018-2024 (USD MILLION)
TABLE 294. SOUTH AFRICA NGAL ANTIBODY MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2025-2030 (USD MILLION)
TABLE 295. SOUTH AFRICA NGAL ANTIBODY MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2024 (USD MILLION)
TABLE 296. SOUTH AFRICA NGAL ANTIBODY MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2025-2030 (USD MILLION)
TABLE 297. SOUTH AFRICA NGAL ANTIBODY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 298. SOUTH AFRICA NGAL ANTIBODY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 299. SOUTH AFRICA NGAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 300. SOUTH AFRICA NGAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 301. SOUTH AFRICA NGAL ANTIBODY MARKET SIZE, BY LABEL TYPE, 2018-2024 (USD MILLION)
TABLE 302. SOUTH AFRICA NGAL ANTIBODY MARKET SIZE, BY LABEL TYPE, 2025-2030 (USD MILLION)
TABLE 303. SOUTH AFRICA NGAL ANTIBODY MARKET SIZE, BY CLINICAL INDICATION, 2018-2024 (USD MILLION)
TABLE 304. SOUTH AFRICA NGAL ANTIBODY MARKET SIZE, BY CLINICAL INDICATION, 2025-2030 (USD MILLION)
TABLE 305. DENMARK NGAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 306. DENMARK NGAL ANTIBODY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 307. DENMARK NGAL ANTIBODY MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2018-2024 (USD MILLION)
TABLE 308. DENMARK NGAL ANTIBODY MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2025-2030 (USD MILLION)
TABLE 309. DENMARK NGAL ANTIBODY MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2024 (USD MILLION)
TABLE 310. DENMARK NGAL ANTIBODY MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2025-2030 (USD MILLION)
TABLE 311. DENMARK NGAL ANTIBODY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 312. DENMARK NGAL ANTIBODY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 313. DENMARK NGAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 314. DENMARK NGAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 315. DENMARK NGAL ANTIBODY MARKET SIZE, BY LABEL TYPE, 2018-2024 (USD MILLION)
TABLE 316. DENMARK NGAL ANTIBODY MARKET SIZE, BY LABEL TYPE, 2025-2030 (USD MILLION)
TABLE 317. DENMARK NGAL ANTIBODY MARKET SIZE, BY CLINICAL INDICATION, 2018-2024 (USD MILLION)
TABLE 318. DENMARK NGAL ANTIBODY MARKET SIZE, BY CLINICAL INDICATION, 2025-2030 (USD MILLION)
TABLE 319. NETHERLANDS NGAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 320. NETHERLANDS NGAL ANTIBODY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 321. NETHERLANDS NGAL ANTIBODY MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2018-2024 (USD MILLION)
TABLE 322. NETHERLANDS NGAL ANTIBODY MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2025-2030 (USD MILLION)
TABLE 323. NETHERLANDS NGAL ANTIBODY MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2024 (USD MILLION)
TABLE 324. NETHERLANDS NGAL ANTIBODY MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2025-2030 (USD MILLION)
TABLE 325. NETHERLANDS NGAL ANTIBODY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 326. NETHERLANDS NGAL ANTIBODY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 327. NETHERLANDS NGAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 328. NETHERLANDS NGAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 329. NETHERLANDS NGAL ANTIBODY MARKET SIZE, BY LABEL TYPE, 2018-2024 (USD MILLION)
TABLE 330. NETHERLANDS NGAL ANTIBODY MARKET SIZE, BY LABEL TYPE, 2025-2030 (USD MILLION)
TABLE 331. NETHERLANDS NGAL ANTIBODY MARKET SIZE, BY CLINICAL INDICATION, 2018-2024 (USD MILLION)
TABLE 332. NETHERLANDS NGAL ANTIBODY MARKET SIZE, BY CLINICAL INDICATION, 2025-2030 (USD MILLION)
TABLE 333. QATAR NGAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 334. QATAR NGAL ANTIBODY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 335. QATAR NGAL ANTIBODY MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2018-2024 (USD MILLION)
TABLE 336. QATAR NGAL ANTIBODY MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, 2025-2030 (USD MILLION)
TABLE 337. QATAR NGAL ANTIBODY MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2024 (USD MILLION)
TABLE 338. QATAR NGAL ANTIBODY MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2025-2030 (USD MILLION)
TABLE 339. QATAR NGAL ANTIBODY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 340. QATAR NGAL ANTIBODY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 341. QATAR NGAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 342. QATAR NGAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 343. QATAR NGAL ANTIBODY MARKET SIZE, BY LABEL TYPE, 2018-2024 (USD MILLION)
TABLE 344. QATAR NGAL ANTIBODY MARKET SIZE, BY LABEL TYPE, 2025-2030 (USD MILLION)
TABLE 345. QATAR NGAL ANTIBODY MARKET SIZE, BY CLINICAL INDICATION, 2018-2024 (USD MILLION)
TABLE 34

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this NGAL Antibody market report include:
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Bio-Techne Corporation
  • Abcam plc
  • BioVendor-Laboratorní medicína a.s.
  • RayBiotech, Inc.
  • Sino Biological Inc.
  • MyBioSource, Inc.
  • Proteintech Group, Inc.
  • Santa Cruz Biotechnology, Inc.

Related Topics

Related Reports

Immunochemicals Market by Product Type (Antibodies, Antigens, Kits), Application (Clinical Research, Diagnostics, Drug Discovery), End User, Technology, Format, Label Type - Global Forecast 2025-2030 - Product Image

Immunochemicals Market by Product Type (Antibodies, Antigens, Kits), Application (Clinical Research, Diagnostics, Drug Discovery), End User, Technology, Format, Label Type - Global Forecast 2025-2030

  • Report
  • 192 Pages
  • Global
From
Conjugation and Labeling Services Market: Distribution by Type of Molecule, Type of Molecular Conjugate / Label, and Key Geographical Regions: Industry Trends and Global Forecasts, 2023-2035 - Product Image

Conjugation and Labeling Services Market: Distribution by Type of Molecule, Type of Molecular Conjugate / Label, and Key Geographical Regions: Industry Trends and Global Forecasts, 2023-2035

  • Report
  • 191 Pages
  • Global
From
Protein Labeling Market by Label Type (Affinity Labeling, Biotin Labeling, Enzymatic Labeling), Application (Flow Cytometry, Immunoassay, Mass Spectrometry), Product Type, End User, Technique - Global Forecast 2025-2030 - Product Image

Protein Labeling Market by Label Type (Affinity Labeling, Biotin Labeling, Enzymatic Labeling), Application (Flow Cytometry, Immunoassay, Mass Spectrometry), Product Type, End User, Technique - Global Forecast 2025-2030

  • Report
  • 184 Pages
  • Global
From
Apoptosis Assays Market by Product Type (Instruments, Reagents), Assay Type (Colorimetric Assay, Enzyme Linked Immunosorbent Assay, Flow Cytometry), Application, End User, Label Technology - Global Forecast 2025-2030 - Product Image

Apoptosis Assays Market by Product Type (Instruments, Reagents), Assay Type (Colorimetric Assay, Enzyme Linked Immunosorbent Assay, Flow Cytometry), Application, End User, Label Technology - Global Forecast 2025-2030

  • Report
  • 185 Pages
  • Global
From
In Situ Hybridization Technology Services Market by Application, End User, Service Type, Probe Type, Label Type, Technology Type - Global Forecast 2025-2030 - Product Image

In Situ Hybridization Technology Services Market by Application, End User, Service Type, Probe Type, Label Type, Technology Type - Global Forecast 2025-2030

  • Report
  • 184 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.